Teleflex Q2 Revenue $570.3M; Completes OEM Divestment, Announces $250M ASR
Teleflex Incorporated reported strong second quarter 2026 financial results, with revenue from continuing operations reaching $570.3 million, a 28.9% increase year-over-year, and adjusted diluted EPS of $1.76. The company completed the divestiture of its OEM business for $1.5 billion, using proceeds to pay down $700 million in debt and repurchase $250 million of common stock, with an additional $250 million Accelerated Share Repurchase announced. While full-year adjusted EPS guidance was increased, revenue growth guidance was slightly reduced due to longer-than-expected integration timelines for the acquired Biotronik Vascular Intervention business. Teleflex also announced FDA approval for EZPLAZ™ Freeze Dried Plasma and progress in its Freesolve™ clinical program.
Key Highlights
- Q2 2026 revenue from continuing operations was $570.3 million, up 28.9% year-over-year.
- Q2 2026 adjusted diluted EPS from continuing operations was $1.76, a 1.7% increase year-over-year.
- Completed the OEM business divestiture for $1.5 billion, with estimated after-tax proceeds of $1.25 billion.
- Paid off $700 million Term Loan A-2 debt associated with the Vascular Intervention business acquisition.
- Repurchased $250 million of common stock in Q2 2026 and announced a new $250 million Accelerated Share Repurchase program.
- Increased full-year 2026 adjusted diluted EPS guidance to a range of $6.90 to $7.20.
- Reduced full-year 2026 pro forma adjusted constant currency revenue growth guidance to 3.50% to 4.50%.
- Received FDA BLA approval for EZPLAZ™ Freeze Dried Plasma and advanced the Freesolve™ clinical program.
Price Impact
More from TFX